Another Step of Success for Dr. Clay Siegall

The Recent Success
Back in January of 2013, Austin, Texas based biotechnology focused company Mirna Therapeutics confirmed that they would have a new member joining their Board of Directors. This new member was revealed to be Dr. Clay Siegall, the CEO and co-founder of Seattle Genetics who would be serving as an outside director. Mirna Therapeutics made this decision based upon their current focus on cancer research, which Dr. Siegall has plenty of experience in. Dr. Paul Lammers, the President and CEO of Mirna Therapeutics, commented on the announcement saying that they were enthusiastic having someone who has the experience that Dr. Siegall has joining their Board of Directors. Dr. Lammers has also stated his expectation of Dr. Siegall helping Mirna Therapeutics in the development of their microRNA-based therapeutics.

About Dr. Siegall
Dr. Clay Siegall co-founded Seattle Genetics in 1998 and currently serves as the company’s President, CEO, and Chairman of the Board of Directors. It was under Dr. Siegall’s leadership that enabled Seattle Genetics to grow and become what it is today. After all, it was thanks to Dr. Siegall’s financial strategies that enabled the company to secure more than $675 million from both public and private finances. Before founding Seattle Genetics, Dr. Siegall had been part of the National Cancer Institute, National Institutes of Health (1988-1991) and then later the Bristol-Myers Squibb Pharmaceutical Research Institute (1991-1997). Dr. Siegall received his PhD in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

About Seattle Genetics
Incorporated on July 15, 1997, the Bothell, Washington based company has been focused upon antibody based cancer treatment methods. Currently the most renown product of the company is the Brentuximab vedotin, better known under the trade name of Adcetris, which is an antibody-drug conjugate that targets the CD30 protein. Other antibody-drug conjugates from Seattle Genetics include SGN-CD19A, SGN-CD33A, SGN-LIV1A, and SGN-CD70A while ASG-22ME and ASG-15ME are still in development and being worked upon in collaboration with the company Agensys. Currently, Seattle Genetics has around 650 employees within the United States.

Dr. Clay Siegall Commits his Life into the Treatment of Cancer

Dr. Clay Siegall went through the University of Maryland from where he was awarded a degree B.S degree in Zoology upon his graduation. He later went further his education at George Washington University from where he earned a Ph.D. in Genetics.

Dr. Clay Siegall has dedicated his career to the research of cancer and the development of its therapy. He is currently heading the way to the treatment of cancer by use of drugs. Most of his time is spent in the medical field in endeavors to come up with the best solution to cancer. With the support of Seattle Genetics Company is commitment in adding more effective and affordable drugs to cure cancer. Dr. Siegall joined the Mirna’s board of directors a company to share his broad experience and achievements in developing the microRNA-based therapeutics.

Dr. Clay Siegall is one of the founders to Seattle Genetics, a biotechnology company established in1998. Dr. Clay Siegall is currently working with the Company in the board of directors as their Chairman, as the Company’ President and as the CEO. Dr. Siegall have played very critical roles in directing the Company towards the achievement of its goals. He guided the Company into activities that greatly raised the company’s capital to over 670 million dollars. In 2011, the Administration of Drug and Food in the United States approved the drugs produced by the Settle Genetics. The company has been making numerous therapies for the cancer basing their principle on antibodies.

Dr. Siegall has also taken the cancer therapy into the literature fields by publishing over 70 works and 15 patents. Other than Mirna and Seattle Genetics, Dr. Siegall has worked with several other medical institutions as a member and also in the top management position. Some of the Institutions include the Washington Biotechnology where he served in the board of Directors, Biomedical Association and also at the Alder Biopharmaceuticals, a private company where he is currently serving as a member of their Board of Directors.